<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444143</url>
  </required_header>
  <id_info>
    <org_study_id>2014-XXXX</org_study_id>
    <nct_id>NCT02444143</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients</brief_title>
  <acronym>Tacrolimus ER</acronym>
  <official_title>A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tacrolimus extended release (Astagraf) has recently been approved by the FDA as a once a day
      dosing regimen. This formulation has the potential to improve compliance. Current dosing
      recommendation for the extended release formulation in renal transplant is 0.15 mg/kg/day
      administered once daily in the morning. There are no specifications on appropriate dosing in
      obese patients or on whether to use actual, ideal or and adjusted weight. It will be
      advantageous to understand the pharmacokinetics of this medication in the obese to determine
      the appropriate dosing regimen. In this study, obese patients will be randomized to receive
      tacrolimus extended release 0.15 mg/kg/day based on either ideal body weight (IBW) or
      adjusted body weight (aBW).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tacrolimus exhibits significant inter- and intra-individual variability of its absorption and
      metabolism. Because of this variability, standard dosing is not an accurate predictor of drug
      exposure. In clinical use, tacrolimus whole blood trough concentrations are measured to
      ensure efficacy and safety. Furthermore, the relatively low bioavailability of tacrolimus is
      thought to be a result of the combination of poor water-solubility, pre-systemic metabolism
      of tacrolimus in the gastrointestinal tract and activity of the P-glycoprotein efflux pump
      found in the enterocytes of the GI tract. Tacrolimus is extensively metabolized by the
      cytochrome P-450 system (CYP3A). The plasma protein binding of tacrolimus is approximately
      99%. Tacrolimus is bound mainly to albumin and alpha-1-acid glycoprotein. The distribution of
      tacrolimus between blood and plasma depends on several factors including hematocrit,
      temperature at the time of plasma separation, drug concentration, and plasma protein
      concentration.

      Pharmacodynamic studies have revealed that, depending on time following transplantation,
      maintaining whole blood trough levels between 5 and 20 ng/mL provides adequate protection
      against acute rejection and limits the occurrence of adverse events. The management of
      tacrolimus blood levels is complicated by variable intra- and inter-patient absorption,
      interaction with food and concomitant medications, and the relatively low bioavailability of
      tacrolimus from the Prograf formulation (17 ± 10% in adult kidney transplant patients).

      Previous studies examining immunosuppressants have shown that drug levels in the immediate
      post-transplant period are a major determinant of subsequent acute cellular rejection. It is
      known that tacrolimus (TAC) &lt; 10 ng/mL is associated with increased rates of acute cellular
      rejection by one month post-transplant.

      There is controversy regarding the appropriate dosing weight to use for immunosuppressants
      (IS). Weights use range from ideal body weight (IBW) to total body weight (TBW) depending on
      the institution and drug being dosed. This becomes particularly important in the obese
      population when there are significant differences between IBW and TBW. Our institution has
      always used IBW for the dosing of all IS due to concerns for nephrotoxicity with initial high
      blood levels of tacrolimus. The concern in obese patients is that the investigators are
      underdosing this population that could be at higher risk for rejection due to higher
      circulating concentrations of pro-inflammatory cytokines. The introduction of the novel use
      of a robotic transplantation procedure at our institution for this patient population has led
      to increasing numbers of transplant in obese recipients; therefore, the investigators decided
      to re-evaluate our dosing protocol. Data from an internal study at UIC show that our use of
      IBW for tacrolimus dosing is not sufficient for the obese population (body mass index [BMI]
      ≥30). The dose used through month 3 was closer to 0.1 mg/kg/day when total body weight was
      utilized. However, the use of an adjusted body weight (aBW) is common for medication dosing
      in obese patients. Adjusted body weight is calculated if the TBW is greater than 30% of the
      calculated IBW. aBW = IBW + 0.4(TBW - IBW). There is limited data available supporting the
      use of either IBW or aBW in dosing tacrolimus within obese patients as these patients are
      typically excluded from most clinical trials, particularly the pharmacokinetic trials. In
      addition, no literature is available comparing the two dosing weights to determine which
      leads to therapeutic concentrations most effectively.

      Summary and Present Study Tacrolimus extended release (Astagraf) has recently been approved
      by the FDA as a once a day dosing regimen. This formulation has the potential to improve
      compliance. Current dosing recommendation for the extended release formulation in renal
      transplant is 0.15 mg/kg/day administered once daily in the morning. There are no
      specifications on appropriate dosing in obese patients or on whether to use actual, ideal or
      and adjusted weight. It will be advantageous to understand the pharmacokinetics of this
      medication in the obese to determine the appropriate dosing regimen. In this study, obese
      patients will be randomized to receive tacrolimus extended release 0.15 mg/kg/day based on
      either ideal body weight (IBW) or adjusted body weight (aBW).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">June 9, 2017</completion_date>
  <primary_completion_date type="Actual">February 28, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Tacrolimus Exposure (AUC-0-24)) in Obese Patients Who Received an Initial TAC -ER Dose of 0.15 mg/kg Using aBW Versus IBW</measure>
    <time_frame>Days 1-14</time_frame>
    <description>Difference in tacrolimus exposure (area under the concentration-time curve from time 0 to 24 hours (AUC-0-24)) in obese patients who received an initial TAC -ER dose of 0.15 mg/kg using aBW versus IBW</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Time to Therapeutic Level</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Difference in the time to a therapeutic tacrolimus trough level in the aBW group compared to the IBW group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>IBW</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tacrolimus extended release 0.15 mg/kg/day based on Ideal Body Weight (IBW)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tacrolimus extended release 0.15 mg/kg/day based on adjusted Body Weight (aBW)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus extended release</intervention_name>
    <arm_group_label>ABW</arm_group_label>
    <arm_group_label>IBW</arm_group_label>
    <other_name>Astagraf XL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject is a recipient of a living donor or deceased donor kidney only transplant

          2. Subject is &gt; 18 years of age

          3. BMI≥30 on POD 0

        Exclusion Criteria:

          1. Multi-organ transplant

          2. Subjects taking tacrolimus pre-transplant (i.e. positive crossmatch transplants or
             re-transplants)

          3. Patients undergoing simultaneous sleeve gastrectomy at the time of transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Illinois Hospital &amp; Health Sciences System</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <results_first_submitted>May 18, 2018</results_first_submitted>
  <results_first_submitted_qc>November 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 7, 2018</results_first_posted>
  <last_update_submitted>November 6, 2018</last_update_submitted>
  <last_update_submitted_qc>November 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Patricia West-Thielke</investigator_full_name>
    <investigator_title>Director of Clinical Research</investigator_title>
  </responsible_party>
  <keyword>Kidney</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 19, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT02444143/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ideal Body Weight- Tacrolimus Extended Release</title>
          <description>tacrolimus extended release (Astagraf) 0.15 mg/kg/day based on Ideal Body Weight (IBW)</description>
        </group>
        <group group_id="P2">
          <title>Adjusted Body Weight-Tacrolimus Extended Release</title>
          <description>tacrolimus extended release (Astagraf) 0.15 mg/kg/day based on adjusted Body Weight (aBW)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9">1 patient withdrawal</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ideal Body Weight- Tacrolimus Extended Release</title>
          <description>tacrolimus extended release (Astagraf) 0.15 mg/kg/day based on Ideal Body Weight (IBW)</description>
        </group>
        <group group_id="B2">
          <title>Adjusted Body Weight-Tacrolimus Extended Release</title>
          <description>tacrolimus extended release (Astagraf) 0.15 mg/kg/day based on adjusted Body Weight (aBW)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="8.6"/>
                    <measurement group_id="B2" value="47.7" spread="14.3"/>
                    <measurement group_id="B3" value="54" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index greater than or equal to 30 on Post Operative Day 0</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Deceased</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Living-unrelated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Living-related</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Pre-transplant dialysis</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.8" spread="36.6"/>
                    <measurement group_id="B2" value="55.8" spread="46.8"/>
                    <measurement group_id="B3" value="50.8" spread="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cause of End Stage Renal Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>hypertension (HTN)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>diabetes mellitus (DM)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>DM + HTN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hospital stay in days</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="6" upper_limit="21"/>
                    <measurement group_id="B2" value="6.5" lower_limit="5" upper_limit="17"/>
                    <measurement group_id="B3" value="6.75" lower_limit="5.5" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index at Transplant</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.2" spread="5.2"/>
                    <measurement group_id="B2" value="43.4" spread="6.8"/>
                    <measurement group_id="B3" value="40.8" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight at Transplant</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116.8" spread="30.2"/>
                    <measurement group_id="B2" value="136.4" spread="30.5"/>
                    <measurement group_id="B3" value="126.6" spread="30.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ideal Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="13.3"/>
                    <measurement group_id="B2" value="71.5" spread="11.8"/>
                    <measurement group_id="B3" value="69.75" spread="12.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Adjusted Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.7" spread="19.5"/>
                    <measurement group_id="B2" value="97.5" spread="17.9"/>
                    <measurement group_id="B3" value="92.1" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in Tacrolimus Exposure (AUC-0-24)) in Obese Patients Who Received an Initial TAC -ER Dose of 0.15 mg/kg Using aBW Versus IBW</title>
        <description>Difference in tacrolimus exposure (area under the concentration-time curve from time 0 to 24 hours (AUC-0-24)) in obese patients who received an initial TAC -ER dose of 0.15 mg/kg using aBW versus IBW</description>
        <time_frame>Days 1-14</time_frame>
        <population>This study randomized de novo kidney transplant recipients who were at least 18 years of age and obese as evidenced by a BMI ≥ 30 on the day of transplantation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ideal Body Weight- Tacrolimus Extended Release</title>
            <description>tacrolimus extended release (Astagraf) 0.15 mg/kg/day based on Ideal Body Weight (IBW)</description>
          </group>
          <group group_id="O2">
            <title>Adjusted Body Weight-Tacrolimus Extended Release</title>
            <description>tacrolimus extended release (Astagraf) 0.15 mg/kg/day based on adjusted Body Weight (aBW)</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Tacrolimus Exposure (AUC-0-24)) in Obese Patients Who Received an Initial TAC -ER Dose of 0.15 mg/kg Using aBW Versus IBW</title>
          <description>Difference in tacrolimus exposure (area under the concentration-time curve from time 0 to 24 hours (AUC-0-24)) in obese patients who received an initial TAC -ER dose of 0.15 mg/kg using aBW versus IBW</description>
          <population>This study randomized de novo kidney transplant recipients who were at least 18 years of age and obese as evidenced by a BMI ≥ 30 on the day of transplantation.</population>
          <units>ng•h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>day 1 AUC 0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.2" spread="51.3"/>
                    <measurement group_id="O2" value="90.0" spread="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 7 AUC 0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268.3" spread="59.9"/>
                    <measurement group_id="O2" value="269.3" spread="101.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 14 AUC 0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355.0" spread="75.4"/>
                    <measurement group_id="O2" value="267.3" spread="101.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Time to Therapeutic Level</title>
        <description>Difference in the time to a therapeutic tacrolimus trough level in the aBW group compared to the IBW group.</description>
        <time_frame>Days 1 to 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ideal Body Weight</title>
            <description>Astagraf 0.15 mg/kg/day based on ideal body weight (IBW)</description>
          </group>
          <group group_id="O2">
            <title>Adjusted Body Weight</title>
            <description>Astagraf 0.15 mg/kg/day based on adjusted body weight (aBW)</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Time to Therapeutic Level</title>
          <description>Difference in the time to a therapeutic tacrolimus trough level in the aBW group compared to the IBW group.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="3.1"/>
                    <measurement group_id="O2" value="5.1" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year 6 months</time_frame>
      <desc>The definition of adverse event and/or serious adverse event, used to collect adverse event information is the same from clinicaltrials.gov.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ideal Body Weight- Tacrolimus Extended Release</title>
          <description>tacrolimus extended release (Astagraf) 0.15 mg/kg/day based on Ideal Body Weight (IBW)</description>
        </group>
        <group group_id="E2">
          <title>Adjusted Body Weight-Tacrolimus Extended Release</title>
          <description>tacrolimus extended release (Astagraf) 0.15 mg/kg/day based on adjusted Body Weight (aBW)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperphosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Delayed graft function</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Patricia West-Thielke</name_or_title>
      <organization>University of Illinois at Chicago</organization>
      <phone>312-996-5695</phone>
      <email>pwest@uic.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

